Yu Shuichang, You Xinran, Liang Hansi, Li Ying, Fu Yi, Zhang Xia, Hu Xiaohan, An Jinnan, Xu Yunyun, Li Fang
Department of Human Anatomy, Histology and Embryology, School of Biology and Basic Medical Sciences, Soochow University, Suzhou, Jiangsu, China.
Department of Nuclear Medicine, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, China.
Heliyon. 2021 Feb 1;7(1):e06120. doi: 10.1016/j.heliyon.2021.e06120. eCollection 2021 Jan.
Acute myocardial infarction (AMI) is the most critical heart disease. Mesenchymal stem cells (MSCs) have been widely used as a therapy for AMI for several years. The human placenta has emerged as a valuable source of transplantable cells of mesenchymal origin that can be used for multiple cytotherapeutic purposes. However, the different abilities of first trimester placental chorion mesenchymal stem cells (FCMSCs) and third trimester placental chorion mesenchymal stem cells (TCMSCs) have not yet been explored. In this study, we aimed to compare the effectiveness of FCMSCs and TCMSCs on the treatment of AMI. FCMSCs and TCMSCs were isolated and characterized, and then they were subjected to in endothelial cell (EC) differentiation induction and tube formation to evaluate angiogenic ability. Moreover, the in effects of FCMSCs and TCMSCs on cardiac improvement were also evaluated in a rat MI model. Both FCSMCs and TCMSCs expressed a series of MSCs surface markers. After differentiation induction, FCMSCs-derived EC (FCMSCs-EC) exhibited morphology that was more similar to that of ECs and had higher CD31 and vWF levels than TCMSCs-EC. Furthermore, tube formation could be achieved by FCMSCs-EC that was significantly better than that of TCMSCs-EC. Especially, FCMSCs-EC expressed higher levels of pro-angiogenesis genes, PDGFD, VEGFA, and TNC, and lower levels of anti-angiogenesis genes, SPRY1 and ANGPTL1. In addition, cardiac improvement, indicated by left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVEDs), left ventricular ejection fraction (LVEF) and left ventricular shortening fraction (LVSF), could be observed following treatment with FCMSCs, and it was superior to that of TCMSCs and Bone marrow MSCs (BMSCs). FCMSCs exhibited a superior ability to generate EC differentiation, as evidenced by in morphology, angiogenic potential and in cardiac function improvement; further, increased levels of expression of pro-angiogenesis genes may be the mechanism by which this effect occurred.
急性心肌梗死(AMI)是最严重的心脏病。间充质干细胞(MSCs)多年来一直被广泛用作AMI的治疗方法。人胎盘已成为间充质来源可移植细胞的宝贵来源,可用于多种细胞治疗目的。然而,孕早期胎盘绒毛膜间充质干细胞(FCMSCs)和孕晚期胎盘绒毛膜间充质干细胞(TCMSCs)的不同能力尚未得到探索。在本研究中,我们旨在比较FCMSCs和TCMSCs治疗AMI的效果。分离并鉴定了FCMSCs和TCMSCs,然后对它们进行内皮细胞(EC)分化诱导和管形成以评估血管生成能力。此外,还在大鼠心肌梗死模型中评估了FCMSCs和TCMSCs对心脏改善的影响。FCSMCs和TCMSCs均表达一系列MSCs表面标志物。分化诱导后,FCMSCs来源的EC(FCMSCs-EC)表现出与ECs更相似的形态,并且比TCMSCs-EC具有更高的CD31和vWF水平。此外,FCMSCs-EC可以实现管形成,明显优于TCMSCs-EC。特别是,FCMSCs-EC表达更高水平的促血管生成基因PDGFD、VEGFA和TNC,以及更低水平的抗血管生成基因SPRY1和ANGPTL1。此外,用FCMSCs治疗后可观察到心脏改善,表现为左心室舒张末期内径(LVEDd)、左心室收缩末期内径(LVEDs)、左心室射血分数(LVEF)和左心室缩短分数(LVSF),并且优于TCMSCs和骨髓间充质干细胞(BMSCs)。FCMSCs表现出产生EC分化的卓越能力,这在体外形态、血管生成潜力和体外心脏功能改善方面得到了证明;此外,促血管生成基因表达水平的增加可能是产生这种效果的机制。